PhRMA’s Global Access to New Medicines Report analyzes what share of new medicines are available in over 70 countries and how long patients wait to receive them. The Global Access to New Medicines Report includes comprehensive comparisons across countries in the G20, OECD and several geographic regions. Policymakers can enable timely patient access to new medicines by having strong intellectual property rights and enforcement, science-based and globally-harmonized regulatory review, and transparent pricing and reimbursement policies that value innovation.